AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose X
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose Y
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Study NCT06717867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Description: Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.
Study NCT06717867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
Study NCT06727110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PILP Cement
Description: PILP cement liner.
Study NCT06727110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PILP Conditioner
Description: PILP solution.
Study NCT06724016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM16390
Description: HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
Study NCT06734520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: super-transplantation in 3 severe β -thalassemia pediatric patients.
Description: Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
Study NCT06735703 — intervention group
Intervention type: DRUG
Intervention: To provide ampicillin sulbactam to pregnant women with premature rupture of membrane
Description: To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
Study NCT06735261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block using 2% lidocaine
Description: A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
Study NCT06735963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meta Quest 3 Virtual Reality
Description: Immersive virtual reality Meta Quest 3 device
Study NCT06735963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Traditional exercise program for knee OA patients
Study NCT06735963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Traditional exercise program for knee OA patients
Study NCT06735963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT06735963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT06735508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA Neoantigen Vaccine
Description: mRNA Neoantigen Vaccine
Study NCT06735508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab is a programmed death-ligand 1 antibody.
Study NCT06735820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Combination therapy of APG-115 and Selumetinib
Study NCT06735820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Combination therapy of APG-115 and Selumetinib
Study NCT06736002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D
Study NCT06736002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D
Study NCT06736002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study NCT06736002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution
Study NCT06735443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexmetedomidine
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
Study NCT06735443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Tramadol
Description: children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
Study NCT06734143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropad
Description: Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
Study NCT06734182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
Description: Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
Study NCT06736106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening
Description: Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
Study NCT06735846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guide wire
Description: Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
Study NCT06735599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry
Description: Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
Study NCT06735599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
Study NCT06735287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bladder sparing set
Description: after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered
Study NCT06735287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RC
Description: Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
Study NCT06734715 — intervention group
Intervention type: OTHER
Intervention: Conservative oxygenation
Description: Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
Study NCT06734715 — intervention group
Intervention type: OTHER
Intervention: Liberal oxygenation
Description: Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
Study NCT06734637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
Study NCT06736054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper 61-PSMA PET/CT
Description: TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
Study NCT06734676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
Study NCT06734676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
Study NCT06734767 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Stress Reduction 8-week course
Description: The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
Study NCT06735586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular control exercise
Description: All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.
Study NCT06735586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuromuscular control exercise and taping
Description: Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
Study NCT06734650 — intervention group
Intervention type: OTHER
Intervention: peripheral waveform collection
Description: The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
Study NCT06736249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenic group
Description: The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.
Study NCT06736249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle harvesting
Description: A piece of discarded muscle during surgery will be collected
Study NCT06736249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle harvesting
Description: A piece of discarded muscle during surgery will be collected
Study NCT05211401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active arm 200 mg
Description: Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
Study NCT05211401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active arm 1000 mg
Description: Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
Study NCT05211401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
Study NCT05760846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAplan®
Description: motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
Study NCT05760846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum®
Description: motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
Study NCT05682924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
Description: In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
Study NCT05505045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Procedures
Description: CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
Study NCT05505045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Procedures
Description: Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
Study NCT05231629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-VRd intensification, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance
Study NCT05231629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AHCT intensification, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance
Study NCT05231629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
Study NCT05231629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AHCT intensification, Dara-R consolidation, Dara-R maintenance
Description: Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
Study NCT05231629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dara-VRd induction
Description: Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
Study NCT06440057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study NCT05452811 — intervention group
Intervention type: PROCEDURE
Intervention: Burch colposuspension
Description: Anti-incontinence surgery for stress urinary incontinence
Study NCT04219813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urinary test
Description: Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
Study NCT06096610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Participants will strength train via linear periodization resistance exercise training.
Study NCT06244641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auto-questionnaires, hetero-questionnaires and Evoked-potentials
Description: Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
Study NCT05444335 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable cardiac monitor -Zio patch
Description: Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
Study NCT06316245 — intervention group
Intervention type: OTHER
Intervention: DASI questionnaire
Description: All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
Study NCT04788576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)
Description: In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
Study NCT05181722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient navigator support
Description: Support of a patient navigator for patients who have experienced an abnormal screening mammogram
Study NCT05279703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 0.03
Description: epinephrine infusion rate of 0.03 mcg/kg/min
Study NCT05279703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.02
Description: epinephrine infusion rate of 0.02 mcg/kg/min